Merck KGaA’s MilliporeSigma is extending a helping hand to Lotte Group as the South Korean conglomerate looks to make an impact on US soil.

MilliporeSigma, Merck KGaA’s life science business in the US and Canada, has signed a memorandum of understanding with the new Lotte biologics business, outlining a planned collaboration to help establish Lotte’s manufacturing capabilities in the US. MilliporeSigma will be a preferred supplier and provide Lotte with technical consulting, training and expertise, products, technologies and manufacturing solutions, according to MilliporeSigma.

Viatris Pharmaceuticals’ Mylan unit is facing yet another recall on a batch of its insulin.

On Tuesday, Viatris — which was formed out of a $12 billion merger between Mylan and Pfizer’s Upjohn unit back in 2020 — announced that Mylan Pharmaceuticals is voluntarily recalling one batch of insulin glargine injection, 3 mL prefilled pens due to potential missing labels.

The batch — numbered BF21002895 — is not the branded Semglee pen, but rather the unbranded insulin pens that are packaged in cartons of five. This batch is being recalled due to the potential for the label to be missing on some pens, and the FDA has been made aware of the recall, the company said.

GSK’s consumer health spinoff Haleon will make its big debut in just over a week — but with some serious debt in tow, according to the company.

When it lists on the London Stock Exchange on July 18, Haleon will have about £10.3 billion (more than $12 billion) in debt on the balance sheet, GSK confirmed on Wednesday. That’s around four times the spinoff’s estimated earnings for the year, according to the UK’s This is Money, which first reported the news.

Months after Sen. Joe Manchin (D-WV) essentially squashed Democrats’ hopes of passing the Build Back Better Act, which included proposals to lower drug prices, a second attempt is reportedly underway that passes muster with all Senate Democrats.

First reported by Punchbowl, Senate Majority Leader Chuck Schumer (D-NY) is submitting a potential reconciliation package to the Senate parliamentarian that includes an agreement backed by all 50 Senate Democrats, including Manchin, to allow Medicare to negotiate prescription drug costs.